BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
102.00
-0.06 (-0.06%)
Apr 29, 2026, 9:30 AM EDT - Market open
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
$431,614
Profits / Employee
-$170,862
Market Cap
25.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
| Revolution Medicines | 883 |
BNTX News
- 7 days ago - Two experimental drugs showed striking early results against pancreatic cancer - WSJ
- 8 days ago - BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 - GlobeNewsWire
- 18 days ago - BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - GlobeNewsWire
- 27 days ago - Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - Reuters
- 5 weeks ago - BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer - GlobeNewsWire
- 7 weeks ago - BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls - Benzinga
- 7 weeks ago - BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 7 weeks ago - One simple reason why BioNTech stock is a raging buy on today's crash - Invezz